Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Sumitomo Mitsui Financial Group

Sumitomo Mitsui Financial Group began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research report sent to investors on Wednesday, Marketbeat reports. The brokerage issued a neutral rating and a $220.00 price objective on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on ALNY. Morgan Stanley raised […]

Related Keywords

Pushkal Garg ,Thomas Tuschl ,David Bartel ,Phillip Zamore ,Northwestern Mutual Wealth Management Co ,Belpointe Asset Management ,Citigroup ,Guardian Wealth Advisors ,Alnylam Pharmaceuticals Company Profile ,Sumitomo Mitsui Financial Group ,News Ratings For Alnylam Pharmaceuticals Daily ,Morgan Stanley ,Securities Exchange Commission ,Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals Price Performance ,Analyst Recommendations For Alnylam Pharmaceuticals ,Alnylam Pharmaceuticals Inc ,Needham Company ,Get Rating ,Moderate Buy ,Lall Franchini ,Exchange Commission ,Asset Management ,Wealth Advisors ,Northwestern Mutual Wealth Management ,Mutual Wealth Management ,Noble Laureate ,Alnylam Pharmaceuticals Daily ,Nasdaq Alny ,Dalny ,Medical ,02043q10 ,Initiated Coverage ,Sumitomo Mitsui Financial Group Inc ,